osimertinib and Pneumonia--Viral

osimertinib has been researched along with Pneumonia--Viral* in 3 studies

Other Studies

3 other study(ies) available for osimertinib and Pneumonia--Viral

Article	Year
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7 Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells	2020
Treatment and Outcome of a Patient With Lung Cancer Infected With Severe Acute Respiratory Syndrome Coronavirus-2. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:5 Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Lopinavir; Lung; Lung Neoplasms; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed	2020
Coronavirus Disease 2019 or Lung Cancer: What Should We Treat? Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:7 Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Lung Neoplasms; Male; Middle Aged; Pandemics; Pneumonia, Viral; Protein Kinase Inhibitors; SARS-CoV-2	2020